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https://doi.org/10.1016/j.celrep.2020.108249SUMMARYKaposi’s sarcoma herpesvirus (KSHV) is an oncogenic human virus and the leading cause of mortality in HIV
infection. KSHV reactivation from latent- to lytic-stage infection initiates a cascade of viral gene expression.
Herewe show how these changes remodel the host cell proteome to enable viral replication. By undertaking a
systematic and unbiased analysis of changes to the endothelial cell proteome following KSHV reactivation,
we quantify >7,000 cellular proteins and 71 viral proteins and provide a temporal profile of protein changes
during the course of lytic KSHV infection. Lytic KSHV induces >2-fold downregulation of 291 cellular proteins,
including PKR, the key cellular sensor of double-stranded RNA. Despite the multiple episomes per cell,
CRISPR-Cas9 efficiently targets KSHV genomes. A complementary KSHV genome-wide CRISPR genetic
screen identifies K5 as the viral gene responsible for the downregulation of two KSHV targets, Nectin-2
and CD155, ligands of the NK cell DNAM-1 receptor.INTRODUCTION
Kaposi’s sarcoma herpesvirus (KSHV) or HHV-8 (human herpes-
virus 8) causes Kaposi’s sarcoma (KS), a highly vascular tumor of
lymphatic and blood vessels (Damania and Cesarman, 2013).
KSHV is latent in healthy subjects but may reactivate in immuno-
compromised individuals with serious consequences. KS is one
of the most common tumors in AIDS patients (Ganem, 2010) and
is linked to two B cell malignancies: primary effusion lymphoma
(PEL) and multicentric Castleman disease (Cesarman et al.,
1995; Soulier et al., 1995). The seroprevalence of KSHV ranges
from 50% in sub-Saharan Africa to 20%–30% in Mediterranean
countries and less than 10% in most of North America, Europe,
and Asia (Uldrick and Whitby, 2011).
Primary KSHV infection results in latent viral infection, the
default state with only few viral genes and microRNAs (miRNAs)
expressed (Ganem, 2010; Schulz, 2006). Upon stimulation, the
latent virus undergoes lytic reactivation that in vivo is triggered
by viral co-infections or immunosuppression (reviewed in Aneja
and Yuan, 2017). In the laboratory, viral reactivation is typically
induced by treatment of latently infected cells with chemical
compounds such as phorbol esters and histone deacetylase
(HDAC) inhibitors. During lytic-stage KSHV infection, the reper-
toire of viral gene products is expressed in a temporal cascade,
resulting in viral replication and the release of new virions.This is an open access article undThe main cell in KS tumors is the highly proliferative spindle
cell, which expresses both lymphatic and vascular endothelial
markers (Gramolelli and Schulz, 2015; Ojala and Schulz, 2014).
These cells also share features with mesenchymal cells as a
result of the endothelial-to-mesenchymal transition process
(EndMT). Up to 90% of spindle cells in KS tumors harbor latent
KSHV genomes, with a small proportion undergoing lytic-stage
viral reactivation (Katano et al., 2000), and both stages of infec-
tion contribute to angiogenic phenotypes (Manners et al., 2018).
The KSHV-RTA (replication and transcription activator) viral
protein is both essential and sufficient for viral reactivation (Lu-
kac et al., 1998, 1999; Sun et al., 1998), and it plays a key role
in the latent- to lytic-stage viral switch. To maintain the latent,
repressive viral state requires silencing of lytic promoters, partic-
ularly the RTA promoter, because RTA is the first protein to be
expressed in lytic-phase infection and initiates the transcrip-
tional activation of multiple downstream viral genes. The RTA
promoter is inhibited by the LANA latent viral protein (Lan
et al., 2004, 2005; Lu et al., 2006), as well as host cell silencing
complexes (Sun et al., 2014; Yada et al., 2006). The switch to
lytic-phase infection is associated with chromatin remodeling
(Lu et al., 2003; Hopcraft et al., 2018) and auto-activation of
the RTA promoter (Deng et al., 2000), resulting in the transcrip-
tional activation of multiple downstream lytic genes (Bu et al.,
2008).Cell Reports 33, 108249, October 13, 2020 ª 2020 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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80 viral proteins, and KSHV, like other herpesviruses, has
evolved multiple immunomodulatory strategies. The best-char-
acterized KSHV-encoded immunoevasins are the K3 and K5
proteins, which downregulate multiple immunoreceptors,
including major histocompatibility complex class I (MHC class
I) molecules, and protect virus-infected cells from immune re-
sponses mediated by cytotoxic T cells and natural killer (NK)
cells (Boname and Lehner, 2011; Coscoy and Ganem, 2000;
Duncan et al., 2006; Ishido et al., 2000a, 2000b; Thomas et al.,
2008a, 2008b). Lytic KSHV replication is also sensed by compo-
nents of the host innate immune system, e.g., IFI16 (Kerur et al.,
2011), MxB (Crameri et al., 2018), and IFIT proteins (Li and Swa-
minathan, 2019). KSHV in turn counteracts host cell restriction
factors, e.g., IFI16 (Roy et al., 2016), and sensing pathways,
e.g., cGAS-STING (Ma et al., 2015; Wu et al., 2015; Zhang
et al., 2016).
Double-stranded RNA sensors such as RIG-I and MDA-5 also
play an important role in lytic KSHV infection (Inn et al., 2011;
West et al., 2014; Zhang et al., 2018; Zhao et al., 2018). Herpes-
viruses have double-stranded DNA (dsDNA) genomes and pro-
duce dsRNA as a by-product of their replication (Jacquemont
and Roizman, 1975) as detected in cells infected by herpes sim-
plex virus (HSV) 1 (Weber et al., 2006) and KSHV (West et al.,
2014). The double-stranded RNA-dependent protein kinase R
(PKR) is a critical host cell factor in the recognition of virus-
derived dsRNA (reviewed in Glaunsinger, 2015). Upon dsRNA
recognition, PKR auto-phosphorylates, dimerizes, and subse-
quently phosphorylates eukaryotic translation initiation factor
2a(eIF2a), leading to inhibition of protein synthesis in virus-in-
fected cells. The importance of the antiviral function of PKR is
emphasized by the finding that many RNA and DNA viruses,
including multiple Herpesviridae family members, counteract
PKR-mediated shutoff of protein synthesis. Depletion of PKR
(e.g., through proteasome degradation) helps prevent host pro-
tein synthesis shutoff, as shown for several viruses, e.g., mouse
adenovirus (Goodman et al., 2019), Toscana virus (Kalveram and
Ikegami, 2013), and Rift Fever Valley virus (Mudhasani et al.,
2016). a- and b-herpesviruses counteract PKR by (1) preventing
its activation by direct binding of viral proteins (Budt et al., 2009;
Hakki et al., 2006; Valchanova et al., 2006; Ziehr et al., 2016), (2)
degrading or shielding dsRNA (Poppers et al., 2000; Sciortino
et al., 2013), and (3) interfering with phosphorylation of eIF2a
(Li et al., 2011).With g-herpesviruses, two lytic Epstein-Barr virus
(EBV) gene products, SM and BILF, prevent PKR activation
(Beisser et al., 2005; Poppers et al., 2003), whereas two lytic
KSHV proteins are reported to interfere with PKR function. Viral
interferon regulatory factor-2 (vIRF-2) blocks eIF2a phosphoryla-
tion (Burýsek and Pitha, 2001), whereas open reading frame
(ORF) 57 interacts with PKR and inhibits dsRNA binding and
PKR autophosphorylation (Sharma et al., 2017).
The expression of KSHV gene products in lytic-phase infec-
tion has been characterized for both mRNA (Arias et al., 2014;
Chandriani et al., 2010) and protein expression (Dresang et al.,
2011). Although host cell transcriptional changes following
lytic KSHV infection have been described (Di Bartolo and Ce-
sarman, 2004; Chandriani and Ganem, 2007) there has been
no analysis of changes to the host cell proteome upon lytic2 Cell Reports 33, 108249, October 13, 2020KSHV infection. Here, we undertake a systematic, unbiased,
quantitative proteomic analysis, from two independent prote-
omics experiments, of lytic KSHV-induced changes in the
cellular proteome of human endothelial cells, a natural target
of KSHV infection. Using tandem mass tag (TMT)-based pro-
teomics, we identify 71 viral proteins and >7,000 cellular pro-
teins, of which 291 are >2-fold downregulated upon KSHV re-
activation, including candidate host resistance/restriction
factors. We provide a time course of viral and cellular protein
expression following KSHV reactivation. Altogether, these
readily searchable datasets provide a resource for viral and
host cell protein changes during the course of latent KSHV re-
activation. We also show that CRISPR-Cas9-based genetics
efficiently depletes KSHV genes from the viral episomal
genome and use this technology to identify viral genes
responsible for the observed cellular phenotypes. We show
that K5 is the dominant KSHV-encoded immunomodulatory
viral protein, affecting expression of at least 48 proteins in
endothelial cells. Among K5 targets, we identify ligands for
the NK cell DNAM-1 receptor and show that PKR, a key
host antiviral protein, is downregulated by KSHV in a K5-inde-
pendent manner.
RESULTS
A Proteomics-Compatible System for KSHV
Reactivation in Endothelial Cells
To investigate how lytic KSHV infection remodels the host cell
proteome, we needed to establish a KSHV-reactivation system
compatible with proteomic-based approaches. We chose to
study KSHV-infected endothelial cells, which like B cells, repre-
sent physiologically relevant in vivo targets of KSHV infection
(Alkharsah et al., 2011). We used HuAR2T-tert, a cell line
derived from conditionally immortalized human umbilical vein
endothelial cells (May et al., 2010) that harbors latent recombi-
nant KSHV encoding GFP and RFP (HuAR2T.rKSHV.219) and is
engineered to report the presence (GFP) and reactivation (RFP)
of virus (Vieira and O’Hearn, 2004). KSHV is reactivated from
these endothelial cells by delivery of exogenous KSHV-RTA
to the latent population. Traditional methods of reactivation, us-
ing RTA-encoding baculovirus and HDAC inhibitors, rarely
exceed >40% KSHV lytic infection, which is not compatible
with reliable proteomic data that require analysis of cells that
are more than 85% infected. To overcome this limitation, we
transduced HuAR2T.rKSHV.219 cells with a lentiviral vector
(LV) expressing KSHV-RTA (LV RTA) without HDAC inhibitors.
Following RTA transduction (Figure 1A), immunoblot analysis
detected early (Kb-ZIP) and late (K8.1) lytic KSHV proteins, indi-
cating the switch from latent- to lytic-phase reactivation (Fig-
ure 1B). Despite some cytopathic effect at 48 h posttransduc-
tion (hpt), most (>90%) reactivated cells harvested at 65 hpt
remained adherent. To enrich for reactivated cells, we per-
formed fluorescence-activated cell sorting (FACS) of the
distinct, RFP-bright population (Figure 1C, 48 and 72 hpt) of
adherent (viable) cells to obtain a 100% homogeneous lytic
KSHV population. A BFP-expressing, lentivirus-transduced
KSHV latent cell population controlled for effects induced by
transduction of lentivirus alone.
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Figure 1. Lytic KSHV Induces Massive Changes in the Proteome of Endothelial Cells
(A and B) Immunoblot analysis of HuAR2T.rKSHV.219 cells transduced with LV RTA, harvested at indicated time points (8, 25, 48, and 74 h), and probed with the
indicated antibody.
(C) Flow cytometry analysis of HuAR2T.rKSHV.219 cells mock-transduced (latent) or transduced with LV RTA and harvested at the indicated time points (24, 48,
and 72 h).
(D) Schematic overview of the quantitative proteomics analysis of the cells with latent versus lytic KSHV infection. HuAR2T.rKSHV.219 cells were transducedwith
LV RTA or control LV BFP, sorted on BFP+ or RFP+, and analyzed by mass spectrometry (MS).
(E) Scatterplot displays pairwise comparison between latent and lytic KSHV infection. Each point represents a single protein, plotted by its log2 (fold change in
abundance) versus the statistical significance (q value) of that change. Value was corrected for multiple hypothesis testing using the method of Benjamini-
Hochberg. Dotted line: q = 0.05.
(F) Flow cytometry analysis of HuAR2T.rKSHV.219 Cas9 cells untreated or treated with reactivation mix and stained with the indicated antibody.
See also Figure S1 and Table S1.
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Proteome of Endothelial Cells
Using this experimental setup, we obtained a homogeneous
population of KSHV-reactivated cells and applied multiplex
TMT-based proteomics to determine the cellular proteomic
changes that occur following KSHV reactivation. Each sample
was performed in triplicate (Figure 1D). We quantified >7,300cellular and viral proteins. More than 1,100 cellular proteins
(15%) were significantly (q < 0.05) upregulated, including four
host gene products known to be induced by the KSHV vGPCR
protein: DUSP5, hIL6, ADAMTS1, and PNP (Glaunsinger andGa-
nem, 2004a), thus validating our approach. More than 3,000 host
cell proteins (41%) showed a significant decrease in expres-
sion, including proteins previously shown to be depleted in lyticCell Reports 33, 108249, October 13, 2020 3
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et al., 2000b; Stevenson et al., 2000), BST2/tetherin (Bartee
et al., 2006), RNA polymerase II (RNA Pol II) subunit RPB1
(Chen et al., 2017), and NK cell receptor ligands ULBP2 and
CD155 (Madrid andGanem, 2012) (Figure 1E; Table S1). Further-
more, KSHV-downregulated proteins included several known
KSHV-K5 targets (Timms et al., 2013). We were able to confirm
lytic KSHV-mediated downregulation of MHC class I, ULBP2,
and CD155 by flow cytometry, validating our proteomics
approach (Figure 1F, left column). Downregulation of three tar-
gets of lytic KSHV—adhesion proteins CD146 and CD97, as
well as Nectin-2, a ligand of NK cell DNAM-1 receptor (Figure 1F,
right column)—was also confirmed.
Viral Proteins Identified by Quantitative Proteomics
Analysis
In addition to host cellular proteins, we quantified 71 canonical
viral proteins (>80% KSHV proteome) and two alternative trans-
lation products, KSHV ORF54A and K3A, which were previ-
ously detected among 63 non-canonical viral products in ribo-
some profiling analysis of lytic KSHV infection (Arias et al.,
2014) (Figures 1E and S1A). We also measured cumulative pro-
tein abundance in the cells with lytic KSHV infection. The most
abundant lytic proteins were ORF25, ORF57, ORF59, and
ORF6 (Figure S1B). Together with 200 cellular proteins, these
4 viral proteins make up 20% of total protein abundance in
the cell. The functions of ORF25, ORF57, and ORF59 are well
defined: ORF25 is a major capsid protein that antagonizes
p53-mediated apoptosis (Chudasama et al., 2015), ORF57 is
a potent posttranscriptional regulator of lytic KSHV gene
expression (Majerciak and Zheng, 2015; Vogt and Bohne,
2016), and ORF59 is a viral DNA polymerase processivity factor
that transports viral DNA polymerase into the nucleus for effi-
cient KSHV DNA synthesis (Chen et al., 2005). The role of
ORF6 is less clear. Recent reports indicate that ORF6 is essen-
tial for lytic KSHV replication (Peng et al., 2014), binds to single-
stranded DNA (ssDNA), and might be involved in viral DNA
replication (Ozgur and Griffith, 2014).
Genetic Screen with a KSHV Genome-wide Library
Identifies K5 as the Viral Gene Responsible for
Downregulation of DNAM-1 Ligands
The cell-surface proteins Nectin-2 and CD155 are both ligands
for the DNAM-1-activating NK cell receptor (Bottino et al.,
2003) and were found to be downregulated by KSHV. Our prote-
omics experiment did not identify the viral gene or genes respon-
sible for downregulation of these cellular proteins. An unbiased
genetic approach using a CRISPR-Cas9 sgRNA library of
KSHV-encoded genes provides a potentially powerful means
to identify viral genes responsible for cellular phenotypes. How-
ever, because multiple copies of episomal KSHV are expressed
in each cell (Dubich et al., 2019) we needed to determine whether
CRISPR-Cas9 could successfully target viral genes. sgRNAs
specific for ORF45 (immediate early), K5 (early), ORF34 (early
late), and K8.1 (late) lytic KSHV genes were transduced into
endothelial cells expressing CRISPR-Cas9, and expression of
the respective viral gene products was analyzed during lytic-
stage infection (Figure 2A). Protein expression of ORF45, K5,4 Cell Reports 33, 108249, October 13, 2020and K8.1 genes was abrogated by their respective sgRNAs (Fig-
ure 2A, lanes 6–8). ORF34 expression could not be analyzed
because of the lack of a specific antibody. Because ORF34 is
essential for late KSHV gene expression (Nishimura et al.,
2017), abrogation of K8.1 expression (Figure 2A, lane 5) serves
as a proxy for successful ORF34 depletion. Levels of the early
Kb-ZIP protein were unaffected in all samples. Having confirmed
that CRISPR-Cas9 specifically and effectively knocks out lytic
genes from viral genomes, we designed a KSHV genome-wide
sgRNA library targeting 143 KSHV genes and 12 miRNAs with
up to 10 sgRNAs per gene for use in linking cellular phenotypes
to the responsible viral gene or genes (Table S2). This library was
used to screen for the KSHV-encoded gene or genes that
target Nectin-2 and CD155 for degradation. Latent
HuAR2T.rKSHV.219 Cas9 cells were transduced with the pooled
sgRNA library to individually deplete viral ORFs and miRNAs
(Figure 2B). Following lytic KSHV activation with RTA lentivirus,
we used FACS to enrich the population of rare lytic cells that
failed to downregulate Nectin-2 and CD155. Sequencing of the
integrated sgRNAs from this enriched population identified K5
as the single viral ORF responsible for downregulation of Nec-
tin-2 and CD155 (Figures 2C and 2D). Subsequent flow cytome-
try analysis confirmed that K5-specific sgRNAs completely
(Nectin-2) or partially (CD155) rescued downregulation of these
ligands by lytic KSHV (Figure 2E). Subsequent analysis showed
that expression of K5 with lentivirus decreased cell-surface
expression of both receptors (Figure 2F). We conclude that a
CRISPR-Cas9 sgRNA library of KSHV-encoded genes is an
effective way of identifying viral genes responsible for cellular
phenotypes and that K5 is both necessary and sufficient for
downregulation of the DNAM-1 ligands Nectin-2 and CD155.
Proteomic Analysis of CRISPR-Cas9-Modified Viral
Genome Identifies Targets of KSHV K5 in Endothelial
Cells
K5 is a potent KSHV-encoded E3 ligase with broad target spec-
ificity (Ashizawa et al., 2012; Boname and Lehner, 2011). The
identification of K5 as the viral gene product responsible for
downregulation of Nectin-2 and CD155 was unanticipated,
because two previous high-throughput proteomic-based
studies of HeLa and KBM7 cells (Bartee et al., 2006; Timms
et al., 2013) did not identify these K5 targets. We reasoned that
there might be additional K5 substrates in endothelial cells and
set out to analyze how K5 affects the host cell proteome in the
context of lytic KSHV infection. Wewanted to compare endothe-
lial cells infected with wild-type (WT) and K5-deficient KSHV, in
which K5 was knocked out using CRISPR-Cas9. Three K5-spe-
cific sgRNAs were identified from the CRISPR KSHV library,
which efficiently rescued downregulation of ICAM-1, awell-char-
acterized K5 target (Figure S2A) (Coscoy and Ganem, 2001). K5
antibody-specific immunoblot analysis of the
HuAR2T.rKSHV.219 Cas9 cells confirmed depletion of K5 in
the samples harboring K5-specific sgRNAs, but not control
(b2-microglobulin [b2m]) sgRNAs (Figure S2B). This efficient
depletion of K5 allowed us to perform a differential proteomics
analysis, comparing WT KSHV-infected cells with CRISPR K5
knockout KSHV-infected cells. Using the experimental setup



































































































Figure 2. KSHV CRISPR Library Screen Identifies K5 as ORF Responsible for Downregulation of the NK Cell Receptor Ligands Nectin-2 and
CD155
(A) Immunoblot analysis of HuAR2T.rKSHV.219 Cas9 cells harboring sgRNAs specific for indicated viral ORFs untreated or treated with reactivation mix and
probed with the indicated antibodies. A non-specific band is labeled with an asterisk.
(B) Schematic flowchart of the genetic screen with the KSHVCRISPR library. HuAR2T.rKSHV.219 Cas9 cells were transduced with the sgRNA library followed by
lytic KSHV cycle induction and stained with CD155- or Nectin-2-specific antibody. Lytic (RFP+) and CD155- or Nectin-2-high cells were selected by FACS and
used for DNA extraction and sequencing.
(C and D) Genetic screens with the KSHV CRISPR library identify K5 as the ORF responsible for downregulation of Nectin-2 and CD155. Each dot represents a
single KSHV ORF or miRNA plotted by the statistical significance (-log p value) of the sgRNA enrichment.
(E) CRISPR-mediated K5 knockout leads to full (Nectin-2) or partial (CD155) rescue of lytic KSHV-induced downregulation of the proteins from the cell surface.
Flow cytometry analysis of HuAR2T.rKSHV.219 Cas9 cells harboring control or K5-specific sgRNAs untreated or treated with reactivation mix and stained with
the indicated antibody.
(F) Flow cytometry analysis of HuAR2T cells transduced with LV K5 or control LV and probed with the indicated antibody.
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KSHV latent cells, (2) KSHV lytic cells transduced with control
sgRNAs, and (3) KSHV lytic cells transduced with a combination
of two K5-specific sgRNAs. Each batch was performed in tripli-
cate. We identified 8,238 host cell proteins in the three groups,
andK5was the only viral protein depleted in the CRISPRK5 pop-
ulation, confirming the specificity of KSHV genome targeting and
validating our approach (Figure 3C). Forty-eight host proteins
were significantly (q < 0.1) downregulated by control lytic
KSHV infection when compared with CRISPR K5 virus (as repre-
sented by blue dots) (Figures 3C–3E; Table S3). Forty-one of the
48 proteins were among 291 cellular substrates that showed >2-
fold downregulation by control lytic KSHV infection. Thirty of the
48 proteins were previously reported as K5 substrates, including
well-characterized targets such asMHC class I (Coscoy and Ga-
nem, 2000; Ishido et al., 2000b), ICAM-1 (Coscoy and Ganem,
2001), PECAM (Mansouri et al., 2006), ALCAM, BST2/tetherin(Bartee et al., 2006), HFE (Rhodes et al., 2010), and K5 targets
from a recent proteomic study (Timms et al., 2013), e.g., mem-
bers of the Ephrin and Plexin receptor families. Eighteen of the
K5 substrates were not previously reported. In addition to Nec-
tin-2 and CD155, plasma membrane proteins included receptor
tyrosine kinases (DDR2, ROR2, and Erbb2), receptor-type tyro-
sine-protein phosphatases (PTPRJ and PTPRE), receptors for
cytokines and growth factors (IL10RB, TRAIL-R2, and IGF2R),
zinc transporter SLC39A3, adhesion molecule CD146, surface
hyaluronidase TMEM2, and PD-L2, a ligand for the PD-1 recep-
tor. Using flow cytometry, we confirmed the K5-dependent
downregulation of 4 of these cell-surface targets (Erbb2,
CD146, PD-L2, and TRAIL-R2) (Figure 3F). EphA2 is particularly
relevant, because it is a cell-surface entry receptor for KSHV
(Hahn et al., 2012) and its downregulation by K5 was confirmed
by both immunoblot (Figure 3G) and flow cytometry (Figure S2C).
Other K5 substrates included three members of the SNARECell Reports 33, 108249, October 13, 2020 5
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Figure 3. CRISPR Proteomics Identifies 48 KSHV K5 Targets in Endothelial Cells
(A) Schematic overview of the quantitative proteomic analysis of cells with lytic versus latent KSHV infection. HuAR2T.rKSHV.219 Cas9 cells harboring control or
K5-specific sgRNAs were transduced with LV RTA or control LV BFP, sorted on BFP+ or RFP+, and analyzed by MS.
(B) KSHV K5 protein significantly (q < 0.1) downregulates 48 proteins in endothelial cells, of which 30 are known K5 targets (left side of blue circle) and 18 proteins
represent K5 targets identified in this study (yellow circle).
(C–E) Scatterplots display pairwise comparison between lytic control and CRISPR K5 (C), latent and lytic control (D), and latent and lytic CRISPR K5 (E) KSHV
infections. Each point represents a single protein, plotted by its log2 (fold change in abundance) versus the statistical significance (p and q value) of that change.
Values were corrected for multiple hypothesis testing using the method of Benjamini-Hochberg. Dotted lines: q = 0.05.
(F) Flow cytometry analysis of HuAR2T cells transduced with LV K5 or control LV and stained with isotype control antibody or antibody specific for the indicated
proteins.
(G and H) Immunoblot analysis of HuAR2T cells transduced with LV K5 or control LV, sorted on GFP+, and probed with the indicated antibody.
See also Figure S2 and Table S3.
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Figure 4. Protein Kinase R Is Downregulated by Lytic KSHV Infection
(A) Flow cytometry analysis of HuAR2T.rKSHV.219 cells with latent (top panel) and lytic (bottom panel) KSHV infection.
(B) Immunoblot analysis of uninfected HuAR2T cells (lane 1) and HuAR2T.rKSHV.219 cells (lanes 2–5) in latent and lytic stages of KSHV infection.
(C) Flow cytometry analysis of HuAR2T.rKSHV.219 cells with stable expression of PKR-4xHA and GFP-HA untreated or treated with reactivation mix and stained
with anti-HA tag antibody. The signal from the HA tag is compared between the RFP+ population (red line) and the latent cells (black line).
(D) Immunoblot analysis of HuAR2T.rKSHV.219 cells transduced with LV RTA or control LV, sorted on RFP+, and probed with the indicated antibody.
(E) qRT-PCR analysis of the host and viral gene expression in cells with the lytic versus latent stage of infection. Data are represented as mean ± SEM.
(F) Immunoblot analysis of HuAR2T.rKSHV.219 Cas9 cells treated with RTA reactivation mix and poly(I:C) and probed with the indicated antibody.
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validated in HuAR2T cells transduced with K5 lentivirus (Figures
3H and S2D). These results demonstrate the utility of the
CRISPR-Cas9 system in efficiently generating viral gene knock-
outs despite the multiple episomal copies of KSHV genomes in
each infected cell. They also highlight the critical role of K5 in re-
modeling the host cell proteome during lytic KSHV infection.
An Early Lytic KSHV Factor Depletes PKR
A prominent lytic KSHV target was PKR; along with protein ki-
nase C (PKC)-related serine/threonine-protein kinases PKN1
and PKN2, PKR was downregulated in a K5-independent
manner (Figures 3D and 3E). PKR is a critical host antiviral pro-
tein (Garcı́a et al., 2007), and its downregulation by lytic KSHVlikely represents a crucial step for virus reactivation. Flow cytom-
etry validated the decrease in PKR levels in the RFP-positive
(KSHV lytic) cell population compared with RFP-negative (latent)
HuAR2T.rKSHV.219 cells (Figure 4A). Next, we assessed PKR
levels in sorted populations of HuAR2T.rKSHV.219 cells trans-
duced with LV RTA or control LV BFP by immunoblot analysis
(Figure 4B). Our data confirmed the marked depletion of PKR
from the KSHV-activated RFP+ populations at 48 or 60 h post-
RTA transduction compared with non-infected or latently in-
fected cells. Furthermore, ectopic hemagglutinin (HA)-tagged
PKR, but not a GFP control, was downregulated by lytic KSHV
(Figure 4C), indicating that the effect is both specific and pro-
moter independent. Phosphonoacetic acid (PAA) is a viral DNA
polymerase inhibitor that blocks late gene expression (SunCell Reports 33, 108249, October 13, 2020 7
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depletion of PKR but did block expression of the late K8.1A/B
proteins (Figure 4D), indicating that downregulation of PKR is
an early lytic event. qRT-PCR analysis comparing mRNA from
RFP+-sorted (lytic) and control (latent) cells showed that lytic
KSHV reduces PKR gene expression by 4.7-fold (2.2-fold on
the log2 scale) (Figure 4E). We also observed downregulation
of LIMD1 (7.1-fold, or 2.8-fold on the log2 scale), a target of
SOX endonuclease (Gaglia et al., 2015). Collectively, these re-
sults show that KSHV infection leads to a transcriptional down-
regulation of PKR, which is caused by an early lytic viral factor,
in a PKR promoter-independent manner. Although we cannot
exclude the possibility that PKR is affected by gene expression
shutoff in lytic infection (Glaunsinger and Ganem, 2004b), we
found that when expressed alone, the viral SOX protein did not
affect PKR protein levels (Figure S3A). In addition to SOX, we
tested several early lytic viral ORFs for PKR depletion, including
ORF57, which is reported to interfere with PKR function (Sharma
et al., 2017) (data not shown; Figure S3B). Despite extensive ef-
forts, we were unable to identify the viral gene or genes respon-
sible for PKR depletion, but we found that poly(I:C)-induced
phosphorylation of eIF2a, a measure of downstream PKR
signaling, was impaired upon KSHV reactivation (Figure 4F).
Proteins and Pathways Dysregulated by Lytic KSHV
Reactivation in Endothelial Cells
Pairwise comparison of two independent proteomics experi-
ments (from Figures 1D and 3A) showed that changes in protein
abundancies correlate well between two datasets (Figure S4). To
gain further insight into KSHV-induced changes in the host cell
proteome, we performed a Gene Ontology (GO) term analysis
of our proteomics datasets using the DAVID platform (Huang
et al., 2009a, 2009b) (Table S4). Among upregulated proteins,
marked enrichment of GO terms related to host cell machinery
required for mRNA processing, translation, folding, and traf-
ficking of proteins was seen (Figures 5A, S5A, and S5B). The
most significantly enriched category was related to protein
folding, mainly members of two families: (1) heat shock protein
70 (HSP70) and (2) all eight subunits of the chaperonin tailless
complex polypeptide 1 (TCP1) ring complex (TRiC) (Figure 5B).
Both families represent therapeutic targets for cancer treatment
(Bassiouni et al., 2016; Boudesco et al., 2018; Carr et al., 2017).
Poly(A) RNA binding was the most abundant category (74 pro-
teins) of upregulated proteins (Figure 5C), and many members
of this group are reported to associate with KSHV ORF57, the
key player in viral mRNA processing (Majerciak and Zheng,
2015; Vogt and Bohne, 2016) (Table 1). The GO terms in the pro-
teins downregulated by lytic KSHV were particularly enriched in
surface receptors, protein kinases, and related biological pro-
cesses, such as cell adhesion and signal transduction (Figures
5D and S5C–S5E). Although many of these proteins represent
K5 targets (Figures 3C–3E), a substantial number of changes
appear to be K5 independent, and lytic-phase KSHV infection
readily validated the downregulation of three of the surface pro-
teins (EphA2, ITGA6, andUFO kinase) by flow cytometry (Figures
5E and 5F). In addition to PKR (Figures 4A and 4B), in the cate-
gory ‘‘protein kinase activity’’ (Figure 5G), we validated depletion
of PKN2 kinase (Figure 5H). Proteins associated with the term8 Cell Reports 33, 108249, October 13, 2020‘‘chromatin binding’’ were also enriched (Figure 5I). Several pro-
teins from this group regulate lytic viral gene expression, e.g.,
HDACs and Rad21 (Gwack et al., 2001; Hu et al., 2019; Lu
et al., 2003; Toth et al., 2017), as well as the nuclear factor kB
(NF-kB) signaling pathway, which plays an important role in the
switch from latent- to lytic-stage KSHV infection (de Oliveira
et al., 2010), e.g., RelB and Ajuba proteins (Feng and Longmore,
2005). Lytic KSHV-mediated depletion of Ajuba was confirmed
by immunoblot analysis of sorted lytic (RFP+) compared with
latent control (BFP+) cells (Figure 5J). Collectively, these results
emphasize the range of host proteins downregulated by lytic
KSHV infection. Although the host cell machinery used by the vi-
rus is upregulated, the expression of cell-surface proteins, ki-
nases, and chromatin binding proteins is predominantly
downregulated.
Kinetic Profiling of the KSHV ORFs Reveals Viral
ProteinsWhose Expression Depends the Activity of Viral
DNA Polymerase
To profile the temporal changes in viral and host protein abun-
dance upon KSHV reactivation, we performed a proteomics
analysis at three time points (36, 48, and 60 h) following reactiva-
tion of HuAR2T.rKSHV.219 Cas9 cells from latent to lytic infec-
tion (Figure 6A). Reliable proteomic data analysis for each time
point requires FACS to enrich a homogeneous population of
>85% lytic infected (RFP+) cells. The acquisition of a homoge-
neous population of lytic RFP+ cells earlier than 36 h postreacti-
vation would have been desirable but was not technically
feasible. To distinguish changes in the host cell proteome medi-
ated by early and late viral proteins, we included samples in
which KSHV reactivation was performed in the presence of
PAA (at the 48 and 60 h time points), an inhibitor of viral DNA
replication. We first sought to determine the expression kinetics
of viral ORFs and performed a hierarchical cluster analysis of all
KSHV proteins quantified in proteomics experiment 3.We gener-
ated temporal and PAA-sensitivity profiles for 62 KSHV ORFs
(Figure 6B) and identified 5 clusters of viral proteins. Clusters 1
and 2 contain a total of 30 proteins, which increase in abundance
from 36 to 60 h upon reactivation and are either insensitive (Fig-
ure 6C) or only mildly sensitive (Figure 6D) to PAA. Proteins from
these clusters were previously reported to exhibit immediate-
early expression kinetics, e.g., ORF45 or K8 (Zhu et al., 1999),
or early expression kinetics, e.g., ORF61, K5, or ORF66 (Sun
et al., 1999; Wang et al., 2010; Watanabe et al., 2020). The 15
proteins in cluster 3 also increase in abundance from 36 to
60 h but were more sensitive to PAA than those in cluster 2 (Fig-
ure 6E). Cluster 4 has 4 proteins that are strongly induced at 36 h
and show moderate sensitivity to PAA treatment (Figure 6F).
Intriguingly, two lytic viral gene products from this cluster,
ORF37 and ORF49, were previously reported to show early ki-
netics (Glaunsinger and Ganem, 2004a; González et al., 2006;
Lu et al., 2004). Cluster 5 contains 12 proteins whose expression
increases in later infection (48–72 h) and that weremarkedly PAA
sensitive (Figure 6G). Expression of many proteins from clusters
3 and 5 was previously reported to depend on viral DNA poly-
merase activity and exhibit late expression kinetics (Lu et al.,
2004). These proteins are predominantly structural components

































































































































Figure 5. DAVID GO Term Analysis of Proteins Dysregulated by Lytic KSHV Infection
(A) Ten most enriched GO terms ranked by statistical significance (p value) in the category ‘‘molecular function’’ among proteins upregulated by lytic KSHV.
(B) Histogram shows the fold change in the abundance of the proteins from the GO term ‘‘unfolded protein binding.’’
(C) Upregulated proteins (red points) from the GO term ‘‘poly(A) RNA binding’’ are highlighted on the scatterplot that displays pairwise comparison between latent
and lytic KSHV infections. Each point represents a single protein, plotted by its log2 (fold change in abundance) versus statistical significance (q value) of that
change. Value was corrected for multiple hypothesis testing using the method of Benjamini-Hochberg. Dotted line: q = 0.05
(D) Ten most enriched GO terms ranked by statistical significance (p value) in the category ‘‘molecular function’’ among proteins downregulated by lytic KSHV.
(E) Validation of lytic KSHV-mediated downregulation of the surface proteins from the GO terms ‘‘integrin binding’’ and ‘‘transmembrane receptor protein tyrosine
kinase activity.’’
(F) Relative abundance of the indicated host proteins in the cells with latent (gray), lytic CRISPR control (blue) and lytic CRISPRK5 (green) KSHV infections. Protein
abundance is calculated as a fraction of the maximum TMT reporter ion intensity. Data are represented as mean ± SEM.
(G–J) Downregulated proteins from the GO terms ‘‘protein kinase activity’’ (G) and ‘‘chromatin binding’’ (I) are highlighted on the scatterplots that display pairwise
comparison between latent and lytic KSHV infection. Each point represents a single protein, plotted by its log2 (fold change in abundance) versus statistical
significance (q value) of that change. Values were corrected for multiple hypothesis testing using themethod of Benjamini-Hochberg. Dotted line: q = 0.05. (H and
J) Immunoblot analysis of HuAR2T.rKSHV.219 cells transducedwith LV RTA or control LV BFP, sorted on BFP+ or RFP+, and probed with the indicated antibody.
Non-specific bands are labeled with an asterisk.
See also Figure S5 and Table S4.
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OPEN ACCESSORF26, ORF62, and ORF65; envelope glycoproteins gB (ORF8),
gH (ORF22), ORF39 (gM), K8.1, and ORF28; and known or pre-
dicted tegument proteins ORF75, ORF64, ORF52, and ORF42
(Butnaru and Gaglia, 2019; Li et al., 2016; Zhu et al., 2005). In
addition to structural proteins, highly PAA-sensitive KSHV geneproducts in cluster 5 include the putative portal protein ORF43
(Deng et al., 2007) andORF20, a lytic protein whichmay promote
KSHV infection through interaction with oligoadenylate synthe-
tase-like protein (OASL) (Bussey et al., 2018). The expression
of both ORFs has been previously shown to be sensitive toCell Reports 33, 108249, October 13, 2020 9
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OPEN ACCESSinhibition of viral DNA polymerase activity (D€unn-Kittenplon
et al., 2019; Lu et al., 2004); our results thus confirm these find-
ings. A hierarchical cluster analysis of all host cell proteins quan-
tified in the proteomics experiment, with temporal and PAA-de-
pendency profiles for more than 8,000 host cell proteins, is
shown (Figure S6A) and includes cellular proteins downregu-
lated, e.g., PKR and PD-L2 (Figure S6B), or upregulated, e.g.,
ADAMTS1 and TPRC4, upon viral reactivation (Figure S6C).
We therefore provide a unique time course of both KSHV and
host cell protein expression following reactivation from latent-
to lytic-phase infection and identify viral ORFs whose expression
depends on viral DNA polymerase activity.
Proteomics Analysis of Cells with a Lytic CRISPR ORF57
KnockdownMutant Reveals a Subset of KSHVORFs that
Requires ORF57 for Efficient Expression
ORF57 is a multifunctional KSHV protein that is known to stabi-
lize viral transcripts, promote nuclear export, and enhance trans-
lation of several lytic viral gene products (Majerciak and Zheng,
2015). Although several studies previously focused on identifica-
tion of KSHV transcripts and proteins whose expression de-
pends on ORF57 (Majerciak et al., 2007; Verma et al., 2015;
Vogt and Bohne, 2016), the complete set of KSHV proteins
that require ORF57 for efficient expression remains unknown.
To generate a KSHV CRISPR ORF57 mutant, we transduced
HuAR2T.rKSHV.219 Cas9 cells with control or ORF57-specific
sgRNAs and analyzed the ORF57 knockdown upon KSHV reac-
tivation by immunoblot. The immunoblot analysis with ORF57-
specific antibody shows efficient CRISPR-Cas9-mediated
depletion of ORF57 in endothelial cells with lytic KSHV infection
(Figure S7A). To compare changes induced by lytic CRISPR
ORF57 and WT KSHV infection, we included sample of cells
with lytic KSHVCRISPRORF57mutant infection, alongwith cells
with control lytic KSHV infection, in proteomics experiment 3.
The analysis of relative abundance of ORF57 in proteomics
experiment 3 confirms efficient CRISPR-Cas9-mediated deple-
tion of ORF57 (Figure S7B). To identify viral ORFs that require
ORF57 for efficient expression, we performed hierarchical clus-
ter analysis of relative protein abundancies of viral ORFs in lytic
control versus CRISPR ORF57 infection (Figure S7C). We
observe three groups of viral proteins in which (1) expression10 Cell Reports 33, 108249, October 13, 2020of KSHV ORFs is strongly inhibited by ORF57 knockdown, (2)
expression is moderately inhibited by ORF57 knockdown, and
(3) expression is independent of or enhanced by ORF57 knock-
down. Thus, our data on KSHV gene products that require
ORF57 for efficient expression confirm the results of previous
studies (Majerciak et al., 2007; Verma et al., 2015; Vogt and
Bohne, 2016) and extend the list of ORF57-dependent viral
gene products.
DISCUSSION
In this study, we established a proteomics-compatible system to
study KSHV reactivation in latently infected human endothelial
cells. This allowed us to ascertain how lytic-stage KSHV infection
alters both the viral and the host cell proteome. We provide a
comprehensive description of changes in >7,000 viral and
cellular proteins during lytic-phase KSHV infection, with a readily
searchable interactive datasheet (Table S1). Our data show that
KSHV uses both transcriptional and posttranscriptional mecha-
nisms to remodel its host cell, with upregulation of cellular pro-
teins related to mRNA biogenesis and protein production and
downregulation of cell-surface receptors, adhesion molecules,
protein kinases, and chromatin binding proteins. Despite the
multiple KSHV episomes per cell, we show that CRISPR-Cas9
is an efficient mechanism for generating viral knockouts of lytic
KSHV genes. By generating a CRISPR library of 1,281 KSHV-en-
coded sgRNAs, we performed KSHV genome-wide genetic
screens that identified K5 as the viral gene responsible for the
downregulation of cellular KSHV targets, two ligands of the
DNAM-1-activating NK cell receptor. Although K5 emerges as
the dominant KSHV-encoded viral gene for downregulating
host cell proteins, the antiviral protein PKR was one of the top
hits downregulated in a K5-independent manner. PKR was
depleted by an early lytic viral factor with kinetics similar to inhi-
bition of eIF2a phosphorylation, suggesting that PKR depletion
may contribute to inhibition of translational shutoff mediated by
lytic KSHV infection.
Previously, lytic KSHV-induced changes in host cells were
analyzed at the mRNA level and revealed global inhibition of
host gene expression, attributed to the viral SOX protein
(ORF37) (Chandriani and Ganem, 2007; Glaunsinger and Ga-
nem, 2004a, 2004b). Most (95%) host transcripts were down-
regulated, with only a small subset (2%) upregulated in lytic
infection. How this gene expression shutoff correlates with
changes in the proteome was unclear. Here we report the first
comprehensive study of lytic KSHV-induced changes to the pro-
teome of endothelial cells. Our results show that lytic KSHV
significantly (q < 0.05) downregulates41%of host cell proteins.
Somewhat surprisingly, 15% of host cell proteins are signifi-
cantly upregulated by lytic infection. This discrepancy may
reflect the poor correlation between transcriptomics and prote-
omics data (reviewed in Haider and Pal, 2013) because of the
involvement of additional factors such as efficiency of mRNA
translation and protein stability.
Our analysis of proteins induced by KSHV reactivation identi-
fied enrichment for host cell components involved in mRNA pro-
cessing, translation, and protein folding. This is not unexpected,
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Figure 6. Kinetic Profiling of KSHV Proteins
(A) Schematic overview of the proteomic analysis of cells with latent versus
lytic infection at 36, 48, and 60 h upon KSHV reactivation.
(B) Hierarchical cluster analysis of all viral proteins quantified. The heatmap
diagram shows temporal and PAA-sensitivity profiles for 62 KSHV ORFs.
Rows and columns represent individual viral ORFs and experimental samples,
respectively.
(C–G) Average temporal and PAA-sensitivity profiles of viral proteins in clusters
1–5. Protein abundance is calculated as a fraction of maximum TMT reporter
ion intensity.
See also Figures S6 and S7.
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enable successful virus replication. Among the upregulated
mRNA binding proteins were several known KSHV ORF57 inter-
action partners, consistent with previous reports demonstrating
a central role for this protein in the processing of KSHV RNAs
(Boyne et al., 2010; Majerciak et al., 2011, 2014; Sharma et al.,
2019). Upregulation of initiation factors supports previous find-
ings on modulation of translation machinery by lytic KSHV (Arias
et al., 2009; Kuang et al., 2011). The finding that KSHV induces
components of Hsp70 and the TRiC complex families is impor-tant, because these may represent therapeutic targets (Bas-
siouni et al., 2016; Boudesco et al., 2018; Carr et al., 2017).
Although their role in lytic KSHV infection is unknown, two
Hsp70 isoforms are essential for lytic KSHV infection (Ba-
quero-Pérez and Whitehouse, 2015).
CRISPR-Cas9 proved an effective means of depleting individ-
ual viral gene products from KSHV genomes in endothelial cells.
CRISPR has recently been successfully used in other human
herpesvirus infections: HSV-1 (Suenaga et al., 2014), HCMV
(King andMunger, 2019), and EBV (van Diemen et al., 2016). Dur-
ing preparation of this manuscript, the CRISPR-mediated modi-
fication of KSHV ORF57 from PEL cell lines was also reported
(BeltCappellino et al., 2019). The main challenge of using
CRISPR in KSHV infection is that multiple viral genomes need
to be targeted within the same cell, reducing the likelihood of
generating a complete viral gene knockout. Here we initially
found that CRISPR provided an effective means of targeting
the KSHV genome for the four viral genes tested. The success
of this technology paved the way for generating a sgRNA
CRISPR library of KSHV-encoded genes to screen for viral genes
responsible for the cellular phenotype of interest, in this case, the
KSHV-mediated downregulation of CD155 and Nectin-2. Using
this approach, we identified K5 as the viral gene responsible
for the downregulation of both receptors, proving the utility of
this screen in assigning cellular phenotypes to viral genes.
Although our genetic screen with the KSHV CRISPR library iden-
tified K5 as a single clear hit, there are limitations to the use of this
technology. In particular, the screen will not be successful if the
phenotype of interest is mediated by a viral gene product essen-
tial for KSHV reactivation or if there is redundancy, i.e., if multiple
viral gene products are responsible for the cellular phenotype.
A combination of CRISPR-based genetics and subsequent
proteomics allowed us to identify endothelial cell proteins regu-
lated by the KSHV K5 gene product. Using TMT-based prote-
omics to compare WT KSHV with CRISPR-mediated K5-defi-
cient KSHV, we identified endothelial cell targets of K5. Two
previous studies reported the cellular targets downregulated
following ectopic K5 expression in both HeLa and KBM7 cells
(Bartee et al., 2006; Timms et al., 2013). Our current approach
identified 48 K5 targets in physiologically relevant endothelial
cells and has the added advantage of being performed in the
context of KSHV infection, as opposed to ectopic K5 viral gene
expression. An interesting finding was the K5-dependent down-
regulation of Nectin-2 and CD155, ligands for the DNAM-1-acti-
vating NK cell receptor (de Andrade et al., 2014). Although
CD155 is known to be downregulated by virus reactivation (Ma-
drid andGanem, 2012), this is the first report of Nectin-2’s deple-
tion by lytic KSHV. K5 protects virus-infected cells from NK cell
lysis through depletion of ICAM-1 (Ishido et al., 2000a), NKG2D
ligands MICA and MICB, and NKp80 ligand AICL (Thomas
et al., 2008a). A role for DNAM-1-mediated control of herpesvirus
infections by NK cells was previously demonstrated for the
HCMV-encoded UL141 protein (Hsu et al., 2015; Prod’homme
et al., 2010; Tomasec et al., 2005), MCMV m20.1 (Lenac Rovis
et al., 2016), and HSV-2-encoded gD protein (Grauwet et al.,
2014; De Pelsmaeker et al., 2018). Another endothelial cell K5
target involved in the NK cell response is TRAIL-R2, a receptor
for the TNFSF10/TRAIL ligand (Walczak et al., 1997). TRAIL isCell Reports 33, 108249, October 13, 2020 11
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target cell killing (Cummins and Badley, 2009). Interestingly,
TRAIL-R2, along with Nectin-2 and CD155, is downregulated
by the HCMV UL141 protein for protection of HCMV-infected
cells from TRAIL-mediated NK cell lysis (Smith et al., 2013). Alto-
gether, these findings extend the repertoire of immune receptors
targeted by KSHV and emphasize the central role of K5 in KSHV
evasion from host cell immune response. The depletion of EphA2
by K5 was particularly significant, because it is an entry receptor
for KSHV (Chakraborty et al., 2012; Hahn et al., 2012). Several vi-
ruses downregulate their entry receptor to prevent dual infection
and enable viral release. This strategy may be particularly impor-
tant for KSHV, because its gL/gH glycoprotein envelope com-
plex has a high affinity for the EphA2 receptor (Großkopf et al.,
2018). The loss of EphA2 would enable efficient virion release
from the Golgi-derived vesicles during KSHV egress in a manner
similar to that reported for tetherin, another K5 target (Mansouri
et al., 2009; Pardieu et al., 2010).
In addition to immune receptors, K5 targets proteins whose
downregulation has less clear functional consequences. A previ-
ous report identified K5-mediated depletion of STX4, a member
of the SNARE family (Bartee et al., 2006), and we now identify
additional SNARE members STX7, STX12, and VAMP8 as K5
targets. Although the reason for their depletion by K5 is unclear,
many members of the SNARE family are involved in cytokine
(Collins et al., 2015; Naegelen et al., 2015; Pagan et al., 2003)
and tumor necrosis factor alpha (TNF-a) secretion (STX7) (Mur-
ray et al., 2005). KSHV K5-mediated STX7 downregulation may
suppress cytokine release, because TNF-a inhibits KSHV gene
transcription in endothelial cells (Milligan et al., 2004).
An intriguing finding was that lytic KSHV infection depleted
host endothelial cells of PKR. Although all Herpesviridae family
members interfere with PKR function, none have been shown
to deplete cells of PKR. KSHV ORF57 is reported to interact
with PKR and inhibit dsRNA binding and PKR auto-phosphoryla-
tion, leading to inhibition of eIF2a phosphorylation (Sharma et al.,
2017). Our results imply that depletion of PKR must also
contribute to the lytic KSHV-mediated block of translational
shutoff. An outstanding question is, which viral gene or genes
downregulate PKR? Its depletion was insensitive to PAA, sug-
gesting involvement of an early viral function. Our attempts to
screen using individual early viral ORF cDNAs or a KSHV
CRISPR library screen for PKR depletion failed to identify signif-
icant hits (data not shown), suggesting PKR is likely to be tar-
geted by more than one viral factor. Our results from two inde-
pendent proteomics experiments show that at the protein
level, lytic KSHV reactivation results in 3.5-fold and 5.3-fold
downregulation of PKR. This is comparable to the qPCR anal-
ysis, which shows that lytic KSHV infection downregulates
PKR mRNA 4.7-fold, but it remains to be determined whether
decreased PKR transcription is the sole contributor to the PKR
depletion observed at the protein level. Transcriptional downre-
gulation of PKR, along with the observation that its depletion is
promoter independent, suggests that PKR may be targeted by
KSHV-encoded miRNAs. However, expression of most KSHV
mRNAs is not enhanced in lytic-phase KSHV infection (Cai
et al., 2005) and the activity of Drosha is inhibited in lytic-stage
KSHV infection (Lin and Sullivan, 2011), making this less likely.12 Cell Reports 33, 108249, October 13, 2020ORF37 (SOX)-mediated shutoff of host gene expression (Glaun-
singer and Ganem, 2004b) is likely to contribute to PKR suppres-
sion, but not to be the sole contributing factor. Isolated expres-
sion of SOX did not affect PKR protein level, suggesting
additional viral genes are involved.
Our proteomic analysis identified 71 canonical viral proteins
(>80% of KSHV proteome) but only two alternative translation
products (KSHV ORF54A and K3A) compared with the 63 alter-
native translation viral products reported from ribosome profiling
in lytic KSHV infection (Arias et al., 2014). Most non-canonical
products are derived from alternate start codons as opposed
to representing novel ORFs, making their differentiation from ca-
nonical ORFs challenging and dependent on the detection of a
small number of unique peptides at the translational start site.
Our time course of protein expression upon viral reactivation
identified 62 KSHV proteins, including those viral proteins whose
expression depends on the viral DNA polymerase and ORF57
protein, together with more than 8,000 endothelial host cell pro-
teins. A transcriptional kinetics analysis of lytic KSHV infection
was previously reported in B cells (Lu et al., 2004; Paulose-Mur-
phy et al., 2001) and endothelial cells (Yoo et al., 2005), but this is
the first proteomics kinetics analysis of lytic KSHV infection.
Furthermore, PAA treatment allowed us to distinguish KSHV pro-
teins whose expression depends on viral DNA polymerase activ-
ity. Expression of 12/62 proteins (19%) was highly PAA sensi-
tive, 33 proteins (53%) show intermediate PAA sensitivity, and
17 proteins (27%)were PAA insensitive. These results correlate
withmicroarray-based analysis of KSHVORF expression with ci-
dofovir (Lu et al., 2004). Lytic gene products reported to show
early mRNA kinetics (ORF37 and ORF49) (Lu et al., 2004; Yoo
et al., 2005) were PAA sensitive at the protein level. This discrep-
ancy might be explained by distinct posttranscriptional regula-
tion, i.e., mediated by machinery that is sensitive to PAA-medi-
ated block of viral DNA polymerase.
In summary, we show how lytic-stage KSHV infection re-
models the host cell proteome. Our results highlight the key
host cell processes modulated by the virus during reactivation
and extend our insight into how KSHV counteracts the host
innate immune response. Our data also provide two important
resources: (1) information on how host cell proteins are affected
by lytic KSHV in endothelial cells and (2) sgRNA library se-
quences specific for the entire set of KSHV-encoded ORFs
and miRNAs to generate CRISPR knockout KSHV mutants.
Further work will be required to identify viral factors responsible
for dysregulation of the host proteins identified in this study and
to elucidate their role in KSHV pathogenesis.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d RESOURCE AVAILABILITYB Lead Contact
B Materials availability
B Data and code availability
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
Resource
ll
OPEN ACCESSd METHOD DETAILS
B Plasmids construction
B Lentivirus production and transduction
B KSHV reactivation for proteomic analysis
B Digestion and TMT Labeling
B High pH Reverse Phase Fractionation
B Mass spectrometry
B CRISPR Cas9-mediated disruption of KSHV ORFs
B Validation of cellular targets of KSHV K5 protein
B Flow cytometry analysis
B Immunoblot analysis
B qRT-PCR analysis
B KSHV CRISPR library design and cloning
B Genetic screens with KSHV CRISPR sgRNA library
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Proteomic data processing and analysis
B Gene Ontology analysis
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
celrep.2020.108249.
ACKNOWLEDGMENTS
The authors thank Dr. Reiner Schulte and the CIMR Flow Cytometry Core Fa-
cility team, David Lukac, Klaus Frueh, Britt Glaunsinger, Jens Bohne, and Su-
Fang Lin for reagents and members of the Lehner and Matheson laboratories
for critical discussions. This work was supported by the Medical Research
Council (grant MR/R001405/1) and the NIHR Cambridge BRC. I.G. was sup-
ported by a Marie Sk1odowska-Curie Individual Fellowship from the European
Union’s Framework Programme for Research and Innovation Horizon 2020
(grant 656511). T.F.S. was funded by the Deutsche Forschungsgemeinschaft
(DFG, German Research Foundation) (SFB900/3-158989968), project C1.
AUTHOR CONTRIBUTIONS
I.G., T.F.S., and P.J.L. conceived the study. I.G. performed experiments and
analyzed the data. J.C.W. performed experiments and analyzed the data.
T.W.M.C. and P.J.L. analyzed the data. T.F.S. contributed essential reagents.
I.G. and P.J.L. wrote the manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: February 3, 2020
Revised: July 13, 2020
Accepted: September 17, 2020
Published: October 13, 2020
REFERENCES
Alkharsah, K.R., Singh, V.V., Bosco, R., Santag, S., Grundhoff, A., Konrad, A.,
St€urzl, M., Wirth, D., Dittrich-Breiholz, O., Kracht, M., and Schulz, T.F. (2011).
Deletion of Kaposi’s sarcoma-associated herpesvirus FLICE inhibitory protein,
vFLIP, from the viral genome compromises the activation of STAT1-responsive
cellular genes and spindle cell formation in endothelial cells. J. Virol. 85,
10375–10388.
Aneja, K.K., and Yuan, Y. (2017). Reactivation and Lytic Replication of Kaposi’s
Sarcoma-Associated Herpesvirus: An Update. Front. Microbiol. 8, 613.
Arias, C., Walsh, D., Harbell, J., Wilson, A.C., and Mohr, I. (2009). Activation of
host translational control pathways by a viral developmental switch. PLoS
Pathog. 5, e1000334.Arias, C., Weisburd, B., Stern-Ginossar, N., Mercier, A., Madrid, A.S., Bellare,
P., Holdorf, M., Weissman, J.S., and Ganem, D. (2014). KSHV 2.0: a compre-
hensive annotation of the Kaposi’s sarcoma-associated herpesvirus genome
using next-generation sequencing reveals novel genomic and functional fea-
tures. PLoS Pathog. 10, e1003847.
Ashizawa, A., Higashi, C., Masuda, K., Ohga, R., Taira, T., and Fujimuro, M.
(2012). The Ubiquitin System and Kaposi’s Sarcoma-Associated Herpesvirus.
Front. Microbiol. 3, 66.
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HEK293T cells (obtained fromATCC) were grown in Iscove’sModified Dulbecco’sMedium (Sigma) supplemented with 10% fetal calf
serum (GIBCO). An endothelial cell line, HuAR2T-tert, conditionally immortalized with doxycycline-dependent human telomerase
reverse transcriptase (hTERT) and simian virus 40 (SV40) T antigen (May et al., 2010) was a kind gift of Dr. Dagmar Wirth (HZI
Braunschweig, Germany). HuAR2T.rKSHV.219 cells is a HuAR2T-tert cell line that harbors latent KHSV genomes (Alkharsah et al.,
2011; Vieira and O’Hearn, 2004). Both cell lines were propagated in EGM-2 Endothelial Medium Bullet Kit (Cat# CC-3156 and
CC-4176, Lonza), with 5% FCS and doxycycline (1ug/ml). All media were supplemented with penicillin (100 units/ml), streptomycin





For pLVX FLAG_RTA vector construction, RTA sequence was amplified from pLenti4-Flag-K-RTA (Ko et al., 2012) (a kind gift of Dr.
Su-Fang Lin, National Institute of Cancer Research, Taiwan) and cloned into pLVX TRE3Gbackbone (Clontech). For pHRSIN-pSFFV-
PKR_4xHA vector construction, the PKR cDNAwas amplified from pSB819-PKR-hum vector (Addgene #20030, kindly deposited by
Harmit Malik) and cloned into pHRSIN-pSFFV-GFP-PGK-Hygro vector. To generate pKLV-U6gRNA(BbsI)-PGKhygro2ABFP vector,
the puromycin resistance cassette in pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (Addgene #50946, kindly deposited by K. Yusa) was re-
placed with hygromycin. For pHRSIN-pSFFV-ORF37(SOX)-IRES-mCherry vector construction, ORF37 sequence was amplified from
pCDEF-strep-SOX vector (a kind gift of Britt Glaunsinger, University of California, Berkeley) and cloned into pHRSIN-pSFFV-MCS-
IRES-mCherry vector. All the cloning procedures were performed using NEBuilder HiFi DNA Assembly master Mix (Cat# E2611L).
Lentivirus production and transduction
293T cells were transfected with a lentivirus expression vector and the packaging vectors pCMVDR8.91 and pMD.G using TransIT-
293 transfection reagent (Mirus) according tomanufacturer’s recommendations. Supernatants were harvested 48 h post transfection
and passed through 0.45 umfilter units. Typically, cells were transduced at anMOI < 1 in 6well plates by centrifugation at 800 g for 1h.
The following drug concentrations were used for selection of transduced cells: puromycin (4 ug/ml), blasticidin (3 ug/mL) or hygrom-
ycin (150 ug/ml).
KSHV reactivation for proteomic analysis
HuAR2T.rKSHV.219 cells (Experiment 1) or HuAR2T.rKSHV.219 Cas9 cells (Experiments 2 and 3) were transducedwith LV RTA or LV
BFP control, harvested 65 h post-transduction (Experiments 1 and 2) or at 36, 48 and 60h upon transduction (experiment 3), fixedwith
2% formaldehyde in PBS for 30 min, washed three times with PBS and sorted on RFP+ or BFP+ markers. In the proteomics exper-
iment 3, where indicated, 500 mM phosphonoacetic acid (PAA) was added 1 hour upon transduction. The resulting samples con-
tained 2,5x10*5 (Experiment 1, Figure 1D), 4x10*5 (Experiment 2, Figure 3A) and 3,5 x10*5 (Experiment 3, Figure 6A) cells each.
Sorted cells were lysed for protein isolation followed by trypsin digest and TMT reporter labeling. The resulting peptides were mixed,
fractionated and analyzed by mass spectrometry.
Digestion and TMT Labeling
Samples were prepared using an IST-NHS digestion kit (Preomics) according to the manufacturer’s instructions with minor modifi-
cation. Briefly, samples were lysed by heating at 95 degrees in lysis buffer for 45 minutes. This is longer than the 10min indicated by
the protocol to effect decrosslinking (Ly et al., 2017). Nucleic acids were sheared by sonication in a Bioruptor sonicator (30 s on/off,
for 10 minutes) (Diagenode). Samples were quantified by BCA assay against a BSA standard curve dissolved in lysis buffer. 25mg of
each sample was reduced, alkylated and digested according to the manufacturer’s protocol. TMT labeling was not conducted prior
to the clean-up step as suggested in the protocol. Instead, samples were cleaned up according to the protocol, dried under vacuum,
resuspended in 21uL 100mM Triethylammonium bicarbonate buffer to which were added 0.2mg of TMT label dissolved in 9mL anhy-
drous acetonitrile (ACN). The reaction was allowed to proceed for 2h at room temperature before pooling of samples. Sample pools
were partially dried under vacuum to remove excess ACN and subsequently diluted to 1mL with 0.1% Trifluoracetic acid (TFA).
Additional formic acid was added to bring the pH < 2. Samples were subjected to SPE clean-up using 50mg tC-18 cartridges (Wa-
ters). Cartridges were wetted with 1mLmethanol, followed by 1mL ACN and equilibrated with 3mL 0.1% TFA. They were then loaded
onto cartridges, washed with 1mL 0.1% TFA and eluted sequentially with 250uL 40% ACN, 60% ACN and 80% ACN. Eluates were
dried under vacuum.
High pH Reverse Phase Fractionation
Samples were subjected to HpHRP fractionation on an Ultimate 3000 UHPLC system (Thermo Scientific) equipped with a 2.1 mm3
15 cm, 1.7m Kinetex Evo C18 column (Phenomenex, UK). Solvent A was 3% ACN, Solvent B was 100% ACN, solvent C was 200 mM
ammonium formate (pH 10). Throughout the analysis, solvent C was kept at a constant 10%. The flow rate was 400 mL/min and UV
was monitored at 280 nm. Samples were loaded in 90% A for 10 min before a gradient elution of 0%–10% B over 10 min (curve 3),
10%–34% B over 21 min (curve 5), 34%–50% B over 5 mins (curve 5) followed by a 10 min wash with 90% B. 15 s (100 mL) fractions
were collected throughout the run. Peptide containing fractions were recombined into 24 fractions (i.e., fractions 1, 25, 49, 73, 97
combined) and dried in a vacuum centrifuge. Fractions were stored at 80C prior to analysis.
Mass spectrometry
Data were acquired on an Orbitrap Fusion mass spectrometer (Thermo Scientific) coupled to an Ultimate 3000 RSLC nano UHPLC
(Thermo Scientific). HpRP fractions were resuspended in 20 ml 5% DMSO 0.5% TFA and 10mL injected. Fractions were loaded at
10 ml/min for 5 min on to an Acclaim PepMap C18 cartridge trap column (300 um 3 5 mm, 5 um particle size) in 0.1% TFA. After
loading a linear gradient of 3%–32% solvent B over 3 hr was used for sample separation over a column of the same stationary phase
(75 mm3 50 cm, 2 mmparticle size) before washing at 90%B and re-equilibration. Solvents were A: 0.1%FA and B:ACN/0.1% FA. Ane5 Cell Reports 33, 108249, October 13, 2020
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target, 50 ms maximum injection time, ions injected for all parallelisable time. MS2: Quadrupole isolation at an isolation width of
m/z 0.7, CID fragmentation (NCE 35) with the ion trap scanning out in rapid mode from m/z 120, 8e3 AGC target, 70 ms maximum
injection time, ions accumulated for all parallelisable time. In synchronous precursor selection mode the top 10 MS2 ions were
selected for HCD fragmentation (65NCE) and scanned out in the orbitrap at 50’000 resolution with an AGC target of 2e4 and a
maximum accumulation time of 120 ms, ions were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a
target time of 3 s. Dynamic exclusion was set to ± 10 ppm for 90 s, MS2 fragmentation was trigged on precursor ions 5e3 counts
and above.
CRISPR Cas9-mediated disruption of KSHV ORFs
Sense and antisense oligonucleotides (Merck) were phosphorylated using T4 PNK (NEB) at 37C for 30 min, annealed at 95C for
5 min and cooled to room temperature. The resulting annealed fragments were treated with BpiI endonuclease (Thermo Fischer Sci-
entific) and cloned into BpiI-treated pKLV-U6gRNA(BbsI)-PGKhygro2ABFP vector using T7 ligase (NEB). The resulting reactions
were transformed in chemically competent E.coliDH10B cells and selected on agar plates with ampicillin. Plasmid DNAwas isolated
using QIAprep Spin Miniprep Kit (QIAGEN) and validated by sequence analysis. For CRISPR Cas9-mediated gene disruption,
HuAR2T.rKSHV.219 cells were first transduced with pHRSIN-pSFFV-Cas9-pPGK-Blasticidin lentivirus vector (Burr et al., 2017) fol-
lowed by blasticidin selection. The cells were transduced with lentiviruses expressing sgRNAs targeting KSHV ORFs: K5 (sgRNA#1
50-GTGGACGACATCCAGCTCTC-30 and sgRNA#2 50-GGCGTAGTCGCCTTAACCTG-30), ORF34 (sgRNA#1 50-GTCGGCCCGA-
CAAAAAGAGG-30 and sgRNA#2 50-CCTCGGGCAGGGTTTCGGGG-30), ORF45 (sgRNA#1 50-GTATGGGCCCGTCTGGCCAG-30
and sgRNA#2 50-TGGGAATATGAACTTCACGG-30), K8.1 (sgRNA#1 50-CATGGCACGCCACCAGACAA-30 and sgRNA#2 50-
GGCATCGGTCAGTTCTGTGG-30) or control sgRNAs (sgRNA#1 50-GTGGTAGCCACCTGGTGCGC-30 and sgRNA#2 50-GCCATC-
TAGGCCTGTGTTGC-30). The cells were selected with hygromycin B for seven days and analyzed by flow cytometry or immunoblot.
For analysis of CRISPR-mediated rescue of ICAM-1 depletion by K5, HuAR2T.rKSHV.219 Cas9 cells were transduced with lentivi-
ruses encoding K5-specific sgRNA#1, sgRNA#2 (sequences are provided above), sgRNA#3 (50- ATACGCGGCAAATAACACCC-30)
or b2-microglobulin (b2M)-targeting sgRNA (50-GGCCGAGATGTCTCGCTCCG-30). To generate CRISPR K5 virus for proteomic
analysis HuAR2T.rKSHV.219 Cas9 cells were transduced with lentiviruses encoding K5-specific sgRNA#1 and sgRNA#2. To
generate CRISPRORF57 virus HuAR2T.rKSHV.219Cas9 cells were transducedwith lentiviruses encodingORF57-specific sgRNA#1
(50-ATTATGAAGGGCATCCTAGA-30) and sgRNA#2 (50-CGATTCGTCAAACTCAGAGG-30).
Validation of cellular targets of KSHV K5 protein
For validation of K5 targets by flow cytometry HuAR2T cells were transduced with pHRSIN K5 GFP or control pHRSIN GFP lentivi-
ruses, harvested 72 hours later and stained with isotype control antibody or antibody specific for Erbb2, EphA2, TRAIL-R2, PD-L2,
CD146 (Biolegend). For validation of targets of K5 by immunoblot, HuAR2T cells were transduced as indicated above and 72 hours
upon transduction GFP-high cell population was selected by FACS, expanded for additional 7 days, lysed and analyzed with anti-
body specific for EphA2 (Santa Cruz Biotechnology), STX7, VAMP8 (R and D Systems) and K5 (kind gift of Klaus Frueh, Vaccine
and Gene Therapy Institute, Oregon Health & Science University).
Flow cytometry analysis
For validation of KSHV-mediated downregulation of cellular proteins by flow cytometry, lytic KSHV cycle was induced by transduc-
tion of HuAR2T.rKSHV.219 cells with LV RTA and treatment with 1.5 mM sodium butyrate (‘RTA reactivation mix’). For cell surface
staining, cells were washed with blocking buffer (4% FCS in PBS) and incubated with the primary antibody specific for CD155, Nec-
tin-2 (Biolegend), ULBP-2, hAxl (R and D Systems), CD97, CD104 (Thermo Fisher Scientific), MHC class I and ICAM-1. The following
antibody were used as isotype controls: mouse IgG1 kappa (Biolegend), mouse IgG2a (Immunotools) and rabbit IgG (Cell signaling)
isotype control antibody. After 1 hour incubation the cells were washed three times with blocking buffer and subsequently incubated
with anti-rabbit or anti-mouse Alexa Fluor 647-conjugated secondary antibody for another hour. All procedures were performed at
4C. For intracellular staining, cells were fixed with 2% formaldehyde for 20 min, washed twice with PBS, permeabilised with 0.2%
Triton x-100 in PBS for 15 min and nonspecific binding sites were blocked with intracellular blocking buffer (1% BSA, 0.1% gelatine,
PBS) for 30 min. The antibodies were diluted in blocking buffer following the recommendations of the manufacturer. Cells were either
incubatedwith anti-HA tag DyLight 650 antibody (Abcam) or with antibody specific for PKR (Cell signaling) for one hour, washed three
timeswith PBS and subsequently incubated with a dye-conjugated secondary antibody for additional hour. Measurements were per-
formed on LSR II Fortessa (Becton Dickinson) flow cytometer and analyzed using FlowJo (TreeStar) software. Ten thousand events
were counted for each sample. Sorts were performed on an Influx cell sorter (Becton Dickinson).
Immunoblot analysis
For validation of the hits identified by proteomics analysis, HuaR2T.rKSHV.219 cells were transduced with BFP control or RTA len-
tiviruses, harvested at 48h or 60h upon transduction, washed with PBS twice and treated with fixing solution (2% formaldehyde in
PBS) for 20minutes.Where indicated, 500 mMphosphonoacetic acid (PAA) was added to the cells 1 hour upon transduction. BFP+ or
RFP+ cell populations were sorted by FACS, lysed in lysis buffer (4% SDS, 200 mM NaCl, 0.01M NaP04 pH 6.0) and treated withCell Reports 33, 108249, October 13, 2020 e6
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bating at 95 degrees for 30min. Total protein amount in the samples wasmeasured by BCA assay (Thermo Fischer Scientific) and the
amount of cell lysate equivalent to 20 ug of protein per lane was resolved on SDS-page gel. The immunoblot analysis was performed
with antibody specific for FLAG-tag (Sigma-Aldrich), KSHV LANA (Leica Biosystems), RTA (kind gift of David Lukac, Rutgers Univer-
sity), ORF57, ORF45, K-bZIP, K8.1 A/B (Santa Cruz Biotechnology), PKR (Cell signaling), PKN2, Ajuba (Thermo Fischer Scientific)
dissolved in PBS with 0.1% Tween-20. For induction of eIF2a phosphorylation, 5x10*5 HuaR2T.rKSHV.219 Cas9 cells were
mock-transduced or transduced with LV RTA and treated with 1.5 mM sodium butyrate for 22h and 34h followed by transfection
with 2 ug of poly I:C (Sigma-Aldrich) using Lipofectamine 2000 (Invitrogen). The cells were harvested 2 hours later, lysed in the pres-
ence of PhosSTOP phosphatase inhibitor (Roche) and analyzed by immunoblot with antibody specific for PKR (Abcam), eIF2alpha
(Thermo Fischer Scientific), Phospho-eIF2alpha (Cell Signaling). Membranes were washed three times in TBS with 0.1% Tween-20
and probed with anti-mouse or anti-rabbit HRP-linked antibody (Cell signaling). Antibodies specific for beta-actin (Sigma-Aldrich)
and alpha-tubulin (Cell signaling) were used as loading controls. Signals were visualized by chemiluminescence using ECL and
ECL Dura western blotting detection reagents and iBright imaging system (Thermo Fischer Scientific).
qRT-PCR analysis
HuAR2T.rKSHV.219 cells were transduced with control BFP (latent) and RTA (lytic) lentiviruses, harvested 60h upon transduction,
fixedwith 2% formaldehyde and sorted on BFP+ andRFP+. Total mRNA from the cells was isolated using RNeasy FFPE kit (QIAGEN)
according to manufacturer specifications. 1 ug of purified RNA was taken for cDNA synthesis using SuperScript III Reverse Tran-
scriptase (Thermo Fisher Scientific) in 50 ul reaction. Host gene-specific primers were designed using Genscript web design tool
(https://www.genscript.com/tools/real-time-pcr-taqman-primer-design-tool), sequences of the primers specific for lytic K8.1 gene
were reported previously (Gramolelli et al., 2020). Transcript levels were determined by quantitative real-time reverse transcriptase
PCR (qPCR) using SYBR green dye (Thermo Fisher Scientific) incorporation and 20 ng of cDNA per reaction. The comparative
threshold cycle method was used to determine the change in gene expression between the samples, using 18S for normalization.
KSHV CRISPR library design and cloning
List containing the coding sequences of canonical KSHV ORFs (GenBank: GQ994935.1), alternative KSHV ORFs (Arias et al., 2014)
and miRNA precursors (Gottwein, 2012) was used as a source file for generation of 19179 sgRNA sequences and calculation their
efficiency score (Xu et al., 2015). The following sgRNAs were excluded from the analysis: (1) containing BsmBI restriction sites,
stretches of four or more thymines or five guanines; (2) those that fully match or align with up to three mismatches with the coding
regions of the human genome; (3) those that align with up to four mismatches with KSHV genome. As more than four mismatches
prevent induction of DSB by Cas9 (Cho et al., 2014; Hsu et al., 2013), the selected sgRNAs will not hit off- targets in the viral genome
and are unlikely to target the host genome. Duplicated sgRNA sequences were merged and ranked on the aforementioned efficiency
score. Typically, ten sgRNAs with the highest score were selected for each KSHV ORF. Due to their small size, several ORFs were
targeted by less than ten sgRNAs, in such cases all the sgRNAs for these ORFs were included in the library. Of note, sgRNAs specific
for KSHV ORF50 (RTA) and vIL6.3 were excluded from the library, because RTA is essential for reactivation and vIL6.3-specific
sgRNAs did not pass the quality filter described above. The resulting library contained 1281 KSHV-specific and 50 non-targeting
sgRNAs from the Activity-Optimized HumanCRISPR Pooled Library (Addgene #1000000067) (Wang et al., 2015) (sequences are pre-
sented in Table S2). sgRNA sequences flanked by BsmBI restriction sites and unique adapters (Doench et al., 2016) were synthesized
as a pool of single-stranded oligonucleotides by Custom Array (Bothell, USA). The pool of KSHV-specific and control sgRNAs was
amplified with subpool-specific primers, cloned into BsmBI-treated pKLV-U6gRNA(BsmBI)-PGKhygro2ABFP vector using T7 DNA
Ligase (NEB), electroporated into Stbl4 Electromax competent cells and selected on ten 15 cm dishes with ampicillin. Plasmid DNA
containing sgRNA library was extracted from 68000 clones (50-fold coverage) and sequenced on Illumina MiniSeq platform.
Genetic screens with KSHV CRISPR sgRNA library
To obtain 1000-fold coverage of each sgRNA in the target cell population, 5x10*6 HuAR2T.rKSHV.219 Cas9 cells were trans-
duced with lentivirus-encoded KSHV sgRNA library at an MOI of 0.3, selected on hygromycin B and expanded for 10 days.
1x10*7 cells stably expressing KSHV sgRNA library were treated with the ‘RTA reactivation mix’ for lytic cycle induction, harvested
65h later, stained with APC-conjugated CD155- or Nectin-2-specific antibody and fixed with 2% formaldehyde in PBS. The
RFP+(lytic) and APC-high (rescued CD155 and Nectin-2 downregulation) cell population was selected by FACS and used for
genomic DNA extraction using QIAamp DNA FFPE Tissue Kit (QIAGEN). Individual integrated sgRNAs were sequenced using the
Illumina MiniSeq platform. Statistical analysis of the enriched sgRNAs in the sorted versus unsorted cell populations was performed
using RSA algorithm (König et al., 2007).
QUANTIFICATION AND STATISTICAL ANALYSIS
Proteomic data processing and analysis
Spectra were searched by Mascot within Proteome Discoverer 2.1 in two rounds of searching. The first search was against the Uni-
Prot Human reference proteome (26/09/17), the KSHV proteome, a database of non-canonical KSHV sequences (Arias et al., 2014)e7 Cell Reports 33, 108249, October 13, 2020
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searched against the human trEMBL database (Uniprot, 26/0917). The following search parameters were used. MS1 Tol: 10 ppm,
MS2 Tol: 0.6 Da, Fixed mods: Ist-alkylation (+113.084064 Da) (C) and TMT (N-term, K), Var mods: Oxidation (M), Enzyme: Trypsin
(/P). MS3 spectra were used for reporter ion-based quantitation with a most confident centroid tolerance of 20 ppm. PSM FDR
was calculated using Mascot percolator and was controlled at 0.01% for ‘high’ confidence PSMs and 0.05% for ‘medium’ confi-
dence PSMs. Normalization was automated and based on total s/n in each channel. Protein/peptide abundance was calculated
and output in terms of ‘scaled’ values, where the total s/n across all reporter channels is calculated and a normalized contribution
of each channel is output. Proteins/peptides satisfying at least a ‘medium’ FDR confidence were taken forward to statistical analysis
in R. This consisted of a moderated t test (Limma) with Benjamini-Hochberg correction for multiple hypotheses to provide a q value
for each comparison (Schwämmle et al., 2013). Hierarchical cluster analysis was performedwithMorpheus analysis software (https://
software.broadinstitute.org/morpheus) using Euclidean distance or one minus Pearson correlation metrics for distance
measurements.
Gene Ontology analysis
Enrichment of Gene Ontology (GO) Molecular Function (GOTERM_MF_Direct) and Biological Process (GOTERM_BP_Direct) terms
from proteins whose expression was dysregulated by lytic KSHV was determined using the Database for Annotation, Visualization
and Integrated Discovery (DAVID) (accessed on 23/8/2019 at https://david.ncifcrf.gov/) with default settings (Huang et al., 2009a,
2009b). Proteins significantly downregulated or upregulated by lytic KSHV infection (FDR-adjusted p < 0.05) in two proteomic exper-
iments (Figures 1D and 3A), quantitated with at least two unique peptides were used as a ‘gene set’ and analyzed against a back-
ground of all proteins quantitated.Cell Reports 33, 108249, October 13, 2020 e8
